TO WHAT EXTENT ARE THE LEARNINGS FROM THE INTRODUCTION OF BIOSIMILARS IN INFLAMMATORY DISEASES TRANSFERABLE TO THE FUTURE INTRODUCTION OF BIOSIMILARS IN ONCOLOGY?

被引：0
|
作者：
Klebba, S. [1 ]
Makin, D. [1 ]
Teale, C. W. [2 ]
机构：
[1] GfK, London, England
[2] GfK, Melton Mowbray, England
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.2321
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN245
引用
收藏
页码：A753 / A753
页数：1
相关论文
共 37 条
  • [31] Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents (vol 34, pg 27, 2020)
    Strand, Vibeke
    Goncalves, Joao
    Hickling, Timothy P.
    Jones, Heather E.
    Marshall, Lisa
    Isaacs, John D.
    BIODRUGS, 2020, 34 (02) : 253 - 253
  • [32] Safety and clinical efficacy of double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicentre study
    Mazza, S.
    Fasci, A.
    Casini, V.
    Ricci, C.
    Munari, F.
    Pirola, L.
    Girelli, C.
    Lupinacci, G.
    Pastorelli, L.
    Cavallaro, F.
    O'Sed, N. Piazza
    Ferraris, L.
    Colucci, A.
    Amato, A.
    Maurizio, V.
    Fiorino, G.
    Caprioli, F.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S342 - S342
  • [33] Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study
    Mazza, Stefano
    Sed, Nicole Piazza O.
    Conforti, Francesco Simone
    Fasci, Alberto
    Rimondi, Alessandro
    Marinoni, Beatrice
    Casini, Valentina
    Ricci, Chiara
    Munari, Francesca
    Pirola, Lorena
    Invernizzi, Pietro
    Girelli, Carlo
    Lupinacci, Guido
    Pastorelli, Luca
    Cavallaro, Flaminia
    Ferraris, Luca
    Colucci, Alice
    Amato, Arnaldo
    Tontini, Gian Eugenio
    Vecchi, Maurizio
    Fiorino, Gionata
    Caprioli, Flavio
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (01): : 172 - 181
  • [34] SAFETY AND CLINICAL EFFICACY OF DOUBLE SWITCH FROM ORIGINATOR INFLIXIMAB TO BIOSIMILARS CT-P13 AND SB2 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES (SCESICS): A MULTICENTRE STUDY.
    Mazza, Stefano
    Fasci', Alberto
    Casini, Valentina
    Ricci, Chiara
    Munari, Francesca
    Pirola, Lorena
    Girelli, Carlo M.
    Lupinacci, Guido
    Pastorelli, Luca
    Cavallaro, Flaminia
    O'Sed, Nicole Piazza
    Ferraris, Luca
    Colucci, Alice
    Amato, Arnaldo
    Vecchi, Maurizio
    Fiorino, Gionata
    Caprioli, Flavio
    GASTROENTEROLOGY, 2020, 158 (06) : S957 - S957
  • [35] SAFETY AND CLINICAL EFFICACY OF THE DOUBLE SWITCH FROM ORIGINATOR INFLIXIMAB TO BIOSIMILARS CT-P13 AND SB2 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES (SCESICS): A MULTICENTER COHORT STUDY
    Mazza, S.
    Sed, Piazza O. N.
    Conforti, F. S.
    Fasci, A.
    Casini, V
    Ricci, C.
    Munari, F.
    Pirola, L.
    Invernizzi, P.
    Girelli, C.
    Lupinacci, G.
    Pastorelli, L.
    Cavallaro, F.
    Ferraris, L.
    Colucci, A.
    Amato, A.
    Tontini, G. E.
    Vecchi, M.
    Fiorino, G.
    Caprioli, F.
    DIGESTIVE AND LIVER DISEASE, 2021, 53 : S159 - S159
  • [36] Comparison of Safety Reports to the FDA from a Pilot Introduction of Peginesatide, a Third Generation Erythropoiesis Stimulating Agent Versus Those from the Usual Care Setting: Manufacturers of Biosimilars and the FDA Should Consider Pilot Introductions of These Agents
    Bennett, Charles L.
    Jacob, Sony
    Georgantopoulos, Peter
    Nichols, Judy
    Macdougall, Iain C.
    BLOOD, 2014, 124 (21)
  • [37] From Bedside to Bench: The Role of Anti-Tumor Necrosis Factor Agents in the Management of Immune-Mediated Inflammatory Diseases Introduction
    Haraoui, Boulos
    Russell, Anthony S.
    Keystone, Edward C.
    JOURNAL OF RHEUMATOLOGY, 2010, 37 : 1 - 1
1234